子宫内膜癌中线粒体融合蛋白2 的 表达及其临床意义

Expression of MFN2 in endometrial carcinoma and its clinical significance

摘要:

目的 探讨线粒体融合蛋白2（MFN2）在子宫内膜癌的表达及其临床意义。方法 利用免疫组 织化学法检测MFN2 在20 例正常子宫内膜（正常子宫内膜组）、33 例非典型增生（非典型增生组）和72 例 子宫内膜癌（子宫内膜癌组）患者石蜡包埋组织中的表达，并分析其与子宫内膜癌临床病理特征及预后的关系。 采用qRT-PCR 检测正常子宫内膜组（20 例）、非典型增生组（23 例）和子宫内膜癌组（40 例）的新鲜冷 冻组织中MFN2 mRNA 相对表达量。结果 子宫内膜癌组MFN2 蛋白阳性率低于非典型增生组和正常子宫 内膜组（P <0.05）。qRT-PCR 结果提示，子宫内膜癌组MFN2 mRNA 相对表达量低于非典型增生组和正常 子宫内膜组（P <0.05）。不同病理类型、分化程度、FIGO 分期及有无淋巴结转移的子宫内膜癌患者MFN2 蛋白高表达率比较，差异有统计学意义（P <0.05）；而不同年龄、是否绝经及肌层浸润深度的MFN2 蛋白高 表达率比较，差异无统计学意义（P <0.05）。生存分析结果显示，MFN2 蛋白低表达子宫内膜癌患者生存时间 短于高表达患者（P <0.05）。结论 MFN2 在子宫内膜癌中的异常表达可能参与肿瘤的发生、发展生物学过程， 检测MFN2 的表达水平可以为子宫内膜癌的诊断和预后判断提供参考。

Abstract:

Objective To investigate the expression and clinical significance of mitochondrial fusion protein 2 (mitofusin-2, MFN2) in endometrial carcinoma. Methods The expression of MFN2 in 20 cases of normal endometrium, 33 cases of atypical hyperplasia and 72 cases of endometrial carcinoma embedded in paraffin was detected by immunohistochemical method, and its relationship with the clinicopathological features and prognosis of endometrial carcinoma was analyzed. The expression of MFN2 mRNA in 20 cases of normal endometrium, 23 cases of atypical hyperplasia and 40 cases of endometrial carcinoma was detected by real time quantitative PCR (qRT-PCR). Results The positive rate of MFN2 protein in endometrial carcinoma was lower than that in atypical hyperplasia and normal endometrial tissue (P < 0.05). The qRT-PCR results indicated that the relative expression of MFN2 mRNA in endometrial carcinoma was lower than that in atypical hyperplasia and normal endometrial tissue (P < 0.05). There were statistically significant differences in the high expression rate of MFN2 protein in endometrial carcinoma of different pathological types, grades, stages and that with or without lymph node metastasis (P < 0.05), while there were no statistically significant differences in the high expression rate of MFN2 protein in patients at different ages, after or before menopause and with different levels of myometrial invasion of endometrial carcinoma (P > 0.05). Survival analysis showed that patients with low expression of MFN2 protein had a shorter survival time than those with high expression of MFN2 protein (P < 0.05). Conclusions The abnormal expression of MFN2 in endometrial carcinoma may participate in the biological process of tumor occurrence and development. The detection of the expression of MFN2 can provide reference for the diagnosis and prognosis of endometrial carcinoma.